Development And Validation Of Stability Indicating RP-HPLC Method For Determination Of Ceritinib

Vaibhav Suresh Adhao, J Sharma, M Thakre


A new, simple, specific, accurate and precise RP-HPLC method was developed for determination of Ceritinib. In the present study, stress testing of Ceritinib was carried out according to ICH guidelines Q1A (R2). Ceritinib was subjected to stress conditions of hydrolysis, oxidation, photolysis and neutral decomposition. Extensive degradation was found to occur in acidic, condition. Mild degradation was observed in basic and at thermal conditions. Successful separation of drug from degradation products formed under stress conditions was achieved on a Hypersil BDS C18 column (250 mm × 4.6 mm, 5.0 μ particle size) using acetonitrile: acetate buffer (pH 3.7 ± 0.05) (50:50 v/v), at a flow rate of 1.0 mL/min and column was maintained at 40˚C. Quantification and linearity was achieved at 272 nm over the concentration range of 5 - 100 μg/mL for Ceritinib. The method was validated for specificity, linearity, accuracy, precision, LOD, LOQ and robustness.


Stability-indicating, HPLC, Ceritinib, Validation, Stress Testing

Full Text:



Chintala R., Sureshbabu K., Nageshwarao M., 2015, Asian J Pharm and Clin Res; vol-8 issue-3; 44-50

Heudi O, Vogel D, Lau YY, Picard F, Kretz O., 2014, Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies. Anal Bioanal Chem; 406(28):7389-96.

Kumar CN, Prathyusha V, Kannappan N., 2014, A novel validated stability indicating RP-HPLC method development for the estimation of ceritinib in its bulk and finished dosage form as per ICH guidelines. Der Pharm Lett;6(5):339-51.

Lanshoeft C, Heudi O, Raccuglia M, Leuthold LA, Picard F, Kretz O., 2015, Ultrafast quantitative MS-based method for ceritinib analysis in human plasma samples from clinical trial. Bioanalysis;7(4):425-35.

Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med; 370(26):1189-97.

Waters NJ., 2014, Evaluation of Drug-Drug Interactions for Oncology Therapies: In-vitro – in-vivo Extrapolation Model-based Risk Assessment. Br J Clin Pharmacol.



  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Indonesian J Pharm indexed by:

analytics View My Stats